| Name | Title | Contact Details |
|---|
bPrescient is a full-service scientific and technology consultancy dedicated to meeting the information management, data science, and analytics needs of the biotech, pharmaceutical, diagnostics, and healthcare industries. With bPrescients industry-leading ecosystem of experts, we offer a unique combination of both depth and breadth of knowledge to provide comprehensive support across: • The entire drug discovery process (from early-stage research to commercialization) • The diagnostics R&D lifecycle • The innovation challenges of the provider / payer domains At bPrescient, we pride ourselves on solving highly complex and difficult challenges. Our clients trust us to provide effective solutions to the problems they face today while anticipating, and helping them avoid, future challenges that catch many organizations unaware. There are three classes of problems we solve for clients: • Strategic & Advisory • Analytical & Scientific • Systems Integration, Design & Build Central to our model is the building of long-term relationships with our clients, which is why we go above and beyond to deliver exceptional results and value to those who need our assistance. Whether you are facing specific challenges today or are thinking about longer-term strategic goals, bPrescient is here to provide the support you need to succeed in the highly competitive biotech, pharmaceutical, diagnostics, and healthcare industries.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Since 1998, Euro Motors set out to position itself as the leader in the automotive industry in the Kingdom of Bahrain and has since come a long way. From a modest start with only BMW, the dealership has managed to acquire premium brands such as MINI, Land Rover, Jaguar, Rolls Royce, Ferrari and Maserati under its impressive banner. In doing so, it has preserved each identity with the utmost integrity and dedication.